We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$60.5M
Cap. Flow %
10.28%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 68.48%
2 Miscellaneous 18.06%
3 Technology 6.31%
4 Industrials 2.63%
5 Communication Services 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTO
126
DELISTED
Vista Outdoor Inc.
VSTO
$135K 0.02%
+6,000
New +$127K
ECL icon
127
Ecolab
ECL
$76.2B
$133K 0.02%
+1,000
New +$129K
AAP icon
128
Advance Auto Parts
AAP
$2.53B
– –
-11,237
Closed -$1.54M
ANAB icon
129
AnaptysBio
ANAB
$1.63B
– –
-25,500
Closed -$708K
HRTX icon
130
Heron Therapeutics
HRTX
$59.9M
– –
-250,000
Closed -$3.75M
NBIX icon
131
PUT
Neurocrine Biosciences
NBIX
$15.4B
– –
-1,500
Closed -$8.01M
OEF icon
132
PUT
iShares S&P 100 ETF
OEF
$20.3B
– –
-500
Closed -$6.95M
SBUX icon
133
Starbucks
SBUX
$110B
– –
-46,631
Closed -$2.72M
SLB icon
134
SLB Ltd
SLB
$77.3B
– –
-34,911
Closed -$2.73M
SPY icon
135
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$804B
– –
-1,000
Closed -$23.8M
TBT icon
136
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$308M
– –
-55,950
Closed -$2.19M
TEVA icon
137
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
– –
-1,500
Closed -$4.74M
TEVA icon
138
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
– –
-172,000
Closed -$5.32M
TRVN
139
DELISTED
Trevena, Inc.
TRVN
– –
-187
Closed -$429K
ZYNE
140
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-100,000
Closed -$2.01M
PRTK
141
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-140,000
Closed -$2.69M
ATHX
142
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-31
Closed -$1K
FPRX
143
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-40,000
Closed -$1.45M
RARX
144
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-60,000
Closed -$1.28M
FOMX
145
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-242,000
Closed -$1.2M
GNMX
146
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-405,000
Closed -$753K
FWP
147
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-15,432
Closed -$2.33M
HZNP
148
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-480,000
Closed -$7.09M
AVXS
149
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-45,000
Closed -$3.42M
KITE
150
DELISTED
Kite Pharma, Inc.
KITE
– –
-35,000
Closed -$2.75M
3 4 5
6
7

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management deployed $60.5M of net new capital in Q2 2017, opening 41 new positions and adding to 30 existing holdings. Its largest new stake was GSK: 360,000 shares worth $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 64% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Shire pic, an estimated $25.5M trimmed.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.